Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 05/23/16 → 01/17/19 |
Funding
- Astellas Pharma Global Development Incorporated: $26,196.50
A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
- Schuster, Michael (PI)
- Gabig, Theodore (CoPI)
- Lan, Fengshuo (CoPI)
- Kiner-Strachan, Bonnie (CoPI)
- Salman, Huda (CoPI)
Project: Research